BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study. 2013

Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.

This work describes the design, synthesis, and evaluation of low-molecular weight peptidic SARS-CoV 3CL protease inhibitors. The inhibitors were designed based on the potent tripeptidic Z-Val-Leu-Ala(pyrrolidone-3-yl)-2-benzothiazole (8; Ki = 4.1 nM), in which the P3 valine unit was substituted with a variety of distinct moieties. The resulting series of dipeptide-type inhibitors displayed moderate to good inhibitory activities against 3CL(pro). In particular, compounds 26m and 26n exhibited good inhibitory activities with Ki values of 0.39 and 0.33 μM, respectively. These low-molecular weight compounds are attractive leads for the further development of potent peptidomimetic inhibitors with pharmaceutical profiles. Docking studies were performed to model the binding interaction of the compound 26m with the SARS-CoV 3CL protease. The preliminary SAR study of the peptidomimetic compounds with potent inhibitory activities revealed several structural features that boosted the inhibitory activity: (i) a benzothiazole warhead at the S1' position, (ii) a γ-lactam unit at the S1-position, (iii) an appropriately hydrophobic leucine moiety at the S2-position, and (iv) a hydrogen bond between the N-arylglycine unit and a backbone hydrogen bond donor at the S3-position.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086782 Coronavirus 3C Proteases 3C proteases that occur in species of CORONAVIRIDAE. 3C Proteases, Coronavirus,3C-Like Proteinase, Coronavirus,Chymotrypsin-Like Main Protease, Coronavirus,Coronavirus 3C Proteinases,Coronavirus 3CLpro Proteases,Coronavirus 3CLpro Proteinase,M(pro) Protein, Coronavirus,Main Proteinase, Coronavirus,Mpro Protein, Coronavirus,3C Like Proteinase, Coronavirus,3C Proteinases, Coronavirus,3CLpro Proteases, Coronavirus,3CLpro Proteinase, Coronavirus,Chymotrypsin Like Main Protease, Coronavirus,Coronavirus 3C-Like Proteinase,Coronavirus Main Proteinase,Coronavirus Mpro Protein,Proteinase, Coronavirus 3CLpro,Proteinases, Coronavirus 3C
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral

Related Publications

Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors.
September 2007, Chembiochem : a European journal of chemical biology,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
April 2008, Bioorganic & medicinal chemistry,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors.
December 2011, Journal of medicinal chemistry,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Design, synthesis and biological evaluation of betulinic acid derivatives as potential inhibitors of 3CL-protease of SARS-CoV-2.
February 2024, Steroids,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Identification of Ebselen derivatives as novel SARS-CoV-2 main protease inhibitors: Design, synthesis, biological evaluation, and structure-activity relationships exploration.
December 2023, Bioorganic & medicinal chemistry,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
October 2023, Chemical biology & drug design,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
May 2009, Bioorganic & medicinal chemistry letters,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Structure features of peptide-type SARS-CoV main protease inhibitors: Quantitative structure activity relationship study.
November 2020, Chemometrics and intelligent laboratory systems : an international journal sponsored by the Chemometrics Society,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.
June 2010, Bioorganic & medicinal chemistry letters,
Pillaiyar Thanigaimalai, and Sho Konno, and Takehito Yamamoto, and Yuji Koiwai, and Akihiro Taguchi, and Kentaro Takayama, and Fumika Yakushiji, and Kenichi Akaji, and Yoshiaki Kiso, and Yuko Kawasaki, and Shen-En Chen, and Aurash Naser-Tavakolian, and Arne Schön, and Ernesto Freire, and Yoshio Hayashi
Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.
May 2023, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!